Antibiotics

So far, the Virginia Mason Medical Center in Seattle has confirmed 33 patients have been infected with Klebsiella pneumoniae bacteria, 9 of whom have died.

Rates of hospital-onset multidrug-resistant P aeruginosa infections have increased significantly in recent years.

The management of hospital-acquired pneumonia requires use of preventive bundles, mitigative of risk factors, and prompt diagnosis with initiation of treatment when highly suspected.

The investigational antibiotic, clovibactin, isolated from soil bacteria demonstrates unique mechanism against conserved site on drug-resistant bacteria.

New evidence suggests that oral transitional therapy may be a promising option for the treatment of infective endocarditis (IE). A retrospective cohort study reveals comparable clinical outcomes between oral and intravenous antibiotic regimens.

Unnecessary antibiotics for viral infections and incorrect prescriptions for bacterial infections have significant consequences, including increased adverse effects and healthcare expenditures.

Investigators revisit an 80-year-old antimicrobial to reduce its toxicity while preserving its activity against drug resistant gram-negative bacteria.

The innovative antibiotic Xacduro has received FDA approval for its efficacy against ventilator-associated bacterial pneumonia caused by Acinetobacter baumannii-calcoaceticus. The intravenous therapy combines sulbactam and durlobactamto target multidrug-resistant and carbapenem-resistant strains.

An antibiotic development stakeholder believes the current paradigm needs to be changed in order for more antibiotics to get FDA approved and reduce multidrug-resistance.

The antibiotic, marketed as Xacduro, is indicated for hospital-acquired bacterial pneumonia (HABP) and ventilator-associated bacterial pneumonia (VABP) caused by susceptible strains of bacteria called Acinetobacter baumannii.

Today, we celebrate the crucial role of infectious disease pharmacists in combating infectious diseases and promoting patient safety.

The mandatory reporting of Antimicrobial Use and Resistance (AUR) by hospitals participating in the CMS Medicare Promoting Interoperability Program beginning next year is a important strategy in curbing the overuse of antibiotics.

A clinician presents data on this antibiotic for these troublesome infections at the ongoing MAD-ID conference.

Sulbactam-durlobactam is efficacious against carbapenem-resistant infections, and Innoviva is preparing for the antibiotic's PDUFA at the end of this month.

Antifungal therapy was frequently initiated before essential diagnostic elements confirmed invasive fungal infections in critically ill COVID-19 patients.

Outpatient parenteral antimicrobial therapy (OPAT) offers benefits for patients as well as providing cost effectiveness; however, it is not without its challenges. Two clinicians provide insights on this modality.

The WHO issued its first ever list of priority antibiotics for pediatrics to encourage research and development targeting needs of that population.

Members of both branches brought it back to gain support and passage of a bill aimed at greater development of antibiotics.

A paradigm shift is emerging when it comes to the clinical approach to prescribing antibiotics. One clinician weighs in on using this class of therapeutics more judiciously.

By addressing ART-related medication errors and increasing linkage to care, antiretroviral stewardship programs can improve management of inpatients with HIV.

This was the first study to compare clinical outcomes in carbapenemase-producing (CP-CRE) and non–carbapenemase-producing (nCP-CRE) infections.

The FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) voted 12-0 in favor of recommending this antibiotic and sets up a PDUFA target action date of May 29.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

Several years after its FDA approval, this antibiotic continues to prove its efficacy in vitro across various pathogens related to these infections.